SM, Casey’s, Gilead, Dominion, Insulet Trending With Analysts

Analysts are intrested in these 5 stocks: ( (SM) ), ( (CASY) ), ( (GILD) ), ( (D) ) and ( (PODD) ). Here is a breakdown of their recent ratings and the rationale behind them.

SM Energy is back in favor with analysts, as John Freeman upgrades the stock to Buy and sees room for it to outperform thanks to a bullish view on oil prices. He argues that SM has already been a big winner from the post‑Iran war oil rally, yet still trades cheaply on 2027 free cash flow and EBITDA, giving investors plenty of upside despite the recent run.

Freeman acknowledges SM’s relatively short inventory life and formerly stretched balance sheet, but says both concerns are easing in a high‑oil environment and after about $700 million of debt reduction. With leverage expected to fall below 1x, buybacks starting in 2Q26, and production steadily growing into 2027, he believes cash flow and value creation can continue.

Casey’s General Stores is drawing fresh enthusiasm as Phillip Blee initiates coverage with a Buy, calling it a rare “defensive, consistent growth” story in consumer stocks. He highlights Casey’s as a best‑in‑class operator whose business is designed to be predictable in both risk‑on and risk‑off markets, a trait investors are increasingly willing to pay for.

Blee notes that while the shares already trade at a seemingly rich multiple of 2027 EBITDA, he thinks that premium is justified by steady low‑ to mid‑teens earnings growth and the potential for further valuation expansion. He sees upside in Casey’s growing prepared‑food offering, long runway for new stores and acquisitions in a fragmented market, and solid balance sheet, though he flags risks from GLP‑1 drugs, fuel, and rural demand.

Gilead Sciences has been upgraded to Buy by Michael Okunewitch, who argues the recent pullback leaves shares trading only in line with big‑pharma peers despite rising growth. He points to stronger‑than‑expected first‑quarter results, higher full‑year guidance, and an HIV franchise that continues to deliver 5%‑6% growth, with long‑acting PrEP drug Yeztugo emerging as a powerful new driver.

Okunewitch believes Gilead now deserves a valuation premium, setting a $165 target based on 2027 earnings. He sees oncology as the real swing factor, led by Trodelvy’s expected move into first‑line breast cancer and pipeline bolstering deals such as Tubulis and Arcellx, while acknowledging skeptics who question whether oncology and liver drugs can ever match HIV’s scale.

Dominion Energy, by contrast, is moving to the sidelines as Angie Storozynski downgrades the utility to Hold amid a complex merger and regulatory backdrop. She notes that the planned tie‑up with NextEra’s NEE may fix some financial issues, including an implied 15% dividend cut that would bring payouts to a more sustainable level.

However, Storozynski warns that Dominion’s regulatory relationships in Virginia are fragile and that approval of the merger is far from guaranteed, given new state commissioners and a history of tension with the utility. With risks around its offshore wind project, an overleveraged balance sheet, and a stock already trading above her prior target, she prefers to watch developments from the sidelines.

Insulet is attracting renewed attention as Steven Lichtman assumes coverage with a Buy rating, arguing that the stock’s pullback has already priced in a long list of worries. He notes that Insulet trades at a discount to faster‑growing med‑tech peers on both earnings and sales, even though it continues to post solid top‑line growth in its Omnipod insulin‑pump franchise.

Lichtman sees two main concerns weighing on sentiment: rising competition in the pharmacy channel and from rival tubeless pumps, and uncertainty over how GLP‑1 weight‑loss drugs might affect the type 2 diabetes market. Yet he highlights encouraging recent prescription trends, a larger U.S. salesforce, expanding international reach, and upcoming launches such as Omnipod 6 and a fully closed‑loop system as potential catalysts for renewed investor confidence.